CAR-T
Elicera CEO: “These early results are very encouraging”
Elicera Therapeutics has communicated promising preliminary data from its Phase I/IIa CARMA study with ELC-301, demonstrating complete metabolic response...
Elicera CEO: "2025 is a key year for us"
For Elicera, 2024 meant important clinical advances and...
Elicera begins collaboration with China Medical University for cancer study
Elicera Therapeutics has initiated a new research collaboration with...
Elicera nears study start of its first clinical CAR T-cell trial CARMA
Elicera Therapeutics is preparing to initiate its first...
Elicera on AstraZeneca's acquisition of Neogene Therapeutics
Interest in cell treatments is on the rise, which is noticeable...
The CAR T revolution in the fight against cancer
CAR T-cell therapies have shown potential to transform...
Elicera about the positive clinical effect in the cancer study
Elicera Therapeutics recently participated in the Oncolytic Virotherapy Summit...
Elicera continues to deliver proof-of-concept data
The Swedish cell and gene therapy company Elicera Therapeutics has...
Elicera Therapeutics takes immuno-oncology to the next level
Immuno-oncology is a large and promising area within...
BioStock's article series on autoimmune disease: The Science
Little is known about the exact causes of...
German company acquired in new billion-dollar deal in immuno-oncology
The American pharmaceutical company Merck announced on Wednesday that...
Biomedical giant pays nearly a billion upfront for early-stage cancer project
Immunotherapy in cancer treatment is red hot for big pharma companies, something...